Jonathan Yen-Wen Yu Sells 9,700 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 9,700 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $72.66, for a total value of $704,802.00. Following the completion of the sale, the chief operating officer owned 54,324 shares of the company’s stock, valued at $3,947,181.84. This trade represents a 15.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Trading Down 0.3%

NASDAQ:IRON opened at $70.16 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The business’s 50-day simple moving average is $68.79 and its 200-day simple moving average is $71.02. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The stock has a market capitalization of $2.68 billion, a PE ratio of -10.60 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Sell-side analysts expect that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IRON has been the subject of a number of research reports. Morgan Stanley increased their target price on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Wedbush restated an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Wells Fargo & Company increased their price objective on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Finally, Truist Financial dropped their target price on Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $105.80.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors have recently added to or reduced their stakes in IRON. ANTIPODES PARTNERS Ltd acquired a new stake in Disc Medicine in the fourth quarter valued at $33,000. Aster Capital Management DIFC Ltd bought a new position in shares of Disc Medicine in the 3rd quarter valued at about $38,000. KBC Group NV acquired a new position in shares of Disc Medicine during the 4th quarter worth about $80,000. Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine during the 4th quarter worth about $141,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Disc Medicine by 36.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after purchasing an additional 490 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.